G1090N not checked

Genfit

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Subjects will receive multiple ascending doses of G1090N up to 1200mg twice daily for 7 consecutive days.”In the company’s words, NCT07110441 on ClinicalTrials.gov
Tested for
Acute-on-Chronic Liver Failure
Main trialPhase 1
“A Phase 1, Open-Label Study to Assess Pharmacokinetics, Safety and Tolerability of G1090N in Healthy Subjects”In the company’s words, NCT07110441 on ClinicalTrials.gov

Other drugs for Acute-on-Chronic Liver Failure

All 5 drugs for Acute-on-Chronic Liver Failure

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Completed 1 Dec 2025 Pharmacokinetic Study on G1090N (Nitazoxanide) Capsules in Healthy Volunteers
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow G1090N

Following is part of Solo: you see every change to G1090N the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in